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Abstract
Study Objectives: To determine the prevalence of self-reported circadian-related sleep disorders, sleep medication and
melatonin use in the New Zealand blind population.
Design: A telephone survey incorporating 62 questions on sleep habits and medication together with validated
questionnaires on sleep quality, chronotype and seasonality.
Participants: Participants were grouped into: (i) 157 with reduced conscious perception of light (RLP); (ii) 156 visually
impaired with no reduction in light perception (LP) matched for age, sex and socioeconomic status, and (iii) 156 matched
fully-sighted controls (FS).
Sleep Habits and Disturbances: The incidence of sleep disorders, daytime somnolence, insomnia and sleep timing
problems was significantly higher in RLP and LP compared to the FS controls (p,0.001). The RLP group had the highest
incidence (55%) of sleep timing problems, and 26% showed drifting sleep patterns (vs. 4% FS). Odds ratios for
unconventional sleep timing were 2.41 (RLP) and 1.63 (LP) compared to FS controls. For drifting sleep patterns, they were
7.3 (RLP) and 6.0 (LP).
Medication Use: Zopiclone was the most frequently prescribed sleep medication. Melatonin was used by only 4% in the RLP
group and 2% in the LP group.
Conclusions: Extrapolations from the current study suggest that 3,000 blind and visually impaired New Zealanders may
suffer from circadian-related sleep problems, and that of these, fewer than 15% have been prescribed melatonin. This may
represent a therapeutic gap in the treatment of circadian-related sleep disorders in New Zealand, findings that may
generalize to other countries.
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Introduction
The primary problem associated with blindness is, of course, the
absence of vision. However, a secondary problem which can have
a major impact on the health and well-being of blind people is the
disruption of their sleep-wake cycles. This problem can result, at
least in part, from the inability of light to synchronise (or entrain)
their circadian clock to the external day–night cycle.
Of the six circadian-related sleep disorders listed in the ICSD
two have particular relevance to the blind: (i) free-running sleep
disorder, in which the circadian clock is not entrained to the 24-
hour day but ‘free-runs’ with an endogenous period somewhat
longer than 24 hours (on average) [1,2,3] and (ii) abnormally
entrained sleep disorder, in which sleep is entrained to 24 hours
but at an incorrect phase angle i.e. sufferers wake either very early
(advanced sleep phase disorder, ASPD) or very late (delayed sleep
phase disorder, DSPD) with respect to societal norms.
Several case reports [4,5,6,7,8,9,10] and studies in small groups
of blind subjects [11,12,13] suggest that sleep-wake timing
disorders occur in up to 50% of blind patients [13]. A survey of
guide-dog owners in the UK proposed a lower incidence of sleep
disorders (14%) [14].
The most comprehensive series of published studies are those
from the University of Surrey in the United Kingdom
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(56 with no conscious perception of light (NLP)) indicated sleep
disturbances in 50% of all respondents, and a higher rate (66%) in
NLP subjects [19]. This group then went on to demonstrate an
increased incidence of abnormal endogenous melatonin rhythms
in subjects lacking conscious light perception (NLP) (n=67)
compared to those with conscious light perception (LP) [16].
Despite reports that sleep timing disorders are a problem in the
blind, the overall incidence in the blind population compared to
the sighted population remains unknown. Central texts such as the
International Classification of Sleep Disorders (ICSD) attest to this
fact, stating that ‘‘the actual incidence [of free-running sleep disorder] is
unknown’’, ‘‘it is thought that over half of totally blind individuals have a
circadian rhythm sleep disorder’’ and ‘‘<70% of blind people report sleep
disorders.’’ [20]
The only large-scale prevalence study of circadian-related sleep
disorders in the blind including sighted controls [21] reported a
much lower incidence of disorders than the ICSD estimates. In
this study, 83% of respondents reported at least one sleep problem
but the rate of free-running sleep disorder was low; only 17% of
totally blind respondents identified drifting sleep patterns (com-
pared to 8% in the sighted controls). Sleep pathologies which were
more prominent in the blind population included shorter sleep
duration, increased sleep latency, nocturnal awakenings and
daytime somnolence [21].
Case studies and clinical trials in small groups of blind subjects
with no conscious light perception (NLP) have shown melatonin to
be effective in stabilising sleep time [8,9,10] and entraining the
biological clock of blind individuals to the 24 hour day
[8,10,15,22,23,24,25,26,27]. Blind subjects receiving melatonin
improved their sleep quality, sleep timing and quality of life
[8,10,15,22,23,24,25,26,27,28]. Few safety data exist for the long
term use of melatonin, but those case reports that are available
suggest no deleterious effects [29].
New Zealand provides a unique opportunity to conduct an
epidemiological survey of sleep disorders in the blind. The Royal
New Zealand Foundation of the Blind (RNZFB) is the sole
organization in New Zealand through which resources are
provided to the blind community. The Foundation’s database is
one of the most comprehensive in the world, with 11,500
members, and listing details of the degree of visual impairment
and underlying cause of blindness for all members.
In addition, due to the interest in socioeconomic factors as
important determinants of health inequalities, New Zealand has
developed a validated ‘‘material deprivation’’ index (NZDep)
based on income, employment, qualifications, living space,
communication, and car and home ownership [30], which is
available for all street addresses in the country. Previous New
Zealand studies have shown increasing deprivation on this scale to
be associated with health problems, including insomnia [31,32].
Major health disparities also exist between Ma ¯ori (the
indigenous people of New Zealand) and non-Ma ¯ori. Ma ¯ori
present an ethnic group in which sleep problems, particularly
sleep apnoea and SIDS, are pronounced [31,32]. Ma ¯ori suffer
from a higher incidence of insomnia compared to non-Ma ¯ori even
after accounting for other factors such as socioeconomic
deprivation. The prevalence of circadian-related sleep disorders
in Ma ¯ori remains unknown.
A further advantage of the New Zealand setting is that the use of
melatonin is quantifiable. As in Australia and the United
Kingdom, melatonin is only available on prescription, which
facilitates the accurate determination of overall rates of use, dosage
and timing of administration (though buying through the internet
and from US sources cannot be controlled).
While free-running rhythms are common in subjects with no
conscious light perception (NLP), abnormally entrained rhythms
are more common in blind individuals with light perception (LP).
However, normally entrained melatonin rhythms have been
reported in monocular subjects suggesting that two eyes may not
be necessary for photo-entrainment in all situations. Furthermore,
illumination of a single eye can result in at least 50% melatonin
suppression (melatonin suppression being used as a marker to infer
presence of circadian photo-entrainment) and in the absence of
one eye there may even be compensation from the remaining eye.
Notwithstanding these findings it is important to note that fully
sighted people suffer from circadian related sleep disorders in
situations of reduced light intensity. This is despite the fact that in
the sleep laboratory, candlelight is sufficient to entrain the human
circadian clock [33]. Because of our lack of understanding about
how much light perception is required for entrainment of the
human circadian clock, in the current study we adopt a cautious
approach to allocating our study groups. The three groups chosen
here were (1) people with reduced light perception (RLP) (no
perception of light in one or both eyes); (2) people with light
perception in both eyes, and (3) fully sighted people (FS). This
approach enables us to identify whether any degree of reduction in
light perception results in an increased incidence of sleep disorders.
Here we present the data from a nationwide survey of (i) the
prevalence of self-reported sleep disorders in the New Zealand
blind community and (ii) the use of sleep medications (including
melatonin) to treat these disorders.
Methods
Participants
This observational study received ethical approval from the
University of Auckland Human Participants Ethics Committee
(REF 2006/008).
Based on previous estimates we calculated that 100 participants
would be required in each of the three study groups in order to
show a statistical difference in the prevalence of sleep disorders
between the groups (p,0.05, power 80%). We recruited and
surveyed 157 members of the Royal New Zealand Foundation of
the Blind (RNZFB) who had no conscious light perception in one
or both eyes (defined as our reduced light perception (RLP) group),
randomly selected from the membership lists. One hundred and
fifty seven members with conscious light perception in both eyes
(LP) matched for age, sex and domicile deprivation coding
(NZDep) to the RLP group were also surveyed, along with 157
fully-sighted matched controls (FS) selected from the electoral rolls.
Overall, two participants withdrew from the study (one in the LP
group and one in the FS group) resulting in final respondent
numbers of RLP 157, LP 156 and FS 156. Admission to the
Foundation requires a full ophthalmic examination confirming a
visual impairment of 6/24 vision or a field of vision of 20u in the
best corrected eye. Details of these examinations are held on the
RNZFB membership records.
The New Zealand domicile deprivation rating (NZDep) is a
nationwide scale in which all street addresses are rated on a scale
of 1 (most privileged) to 10 (least privileged). Domicile deprivation
codes were recorded for all participants in the RLP group, and
respondents in the LP and FS groups were matched (to the extent
this was practicable) to the RLP group.
Participants in the RLP and LP groups were further broken
down into sub-groups based on the level of light perception in each
eye. The primary rationale for this was to enable the direct
comparison of the prevalence of sleep disorders between those
subjects with no light perception (NLP) in either eye, a group
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perception’ group. There were three sub-groups in the RLP group:
NLP-NLP subjects with no light perception in either eye, NLP-LP
subjects with no perception of light in one eye and light perception
in the other, and NLP-S subjects with no light perception in one
eye and sight in the other. Similarly, the LP group had three sub-
groups: LP-LP, LP-S and S-S (the last group being those subjects
who meet the criteria for admission to the RNZFB but who have
some sight in both eyes).
Half of the entire membership of RNZFB (approximately 6,000
people) were sent a letter by the Foundation, informing them of
the study and asking them to identify themselves if they did not
wish to be contacted. A second letter providing specific
information about the study was then sent to 3,000 randomly
selected potential participants. In order to obtain a sample size of
at least 150 in each group, 781 randomly selected members from
the 3,000 potential participants (456 RLP and 325 LP) were
subsequently telephoned and invited to participate in the survey.
This procedure was repeated for the FS control group. A toll free
number was active throughout the study to enable participants to
contact the investigators at no cost. In accordance with ethical
guidelines informed consent was obtained over the telephone from
all participants (as many visually impaired subjects were unable to
read) and consents were stored in coded computer voice files.
Survey
A 30 minute telephone-based survey with 62 questions was
developed and piloted on 30 subjects (excluded from the main
survey). The refined survey was conducted between February 2006
and May 2007. This survey (see Supporting Information S1)
included:
(i) questions regarding self-reported sleep habits and sleep
problems: sleep-apnoea, restless sleep, unconventional
sleep times, sleep latency, nocturnal restlessness, early
morning wakening, sleepwalking/talking, non-restorative
sleep, daytime somnolence, bruxism; and sleep medication
use;
(ii) questions designed to identify circadian-related sleep
disorders:
‘‘Do you always experience difficulties sleeping or do
your sleep problems occur intermittently with alternat-
ing periods of good and bad sleep?’’
‘‘Do these periods of bad sleep occur at regular
intervals?’’
‘‘How long, in days, is it between the start of one period
of bad sleep and the start of the next period of bad
sleep?’’
‘‘How long, in days, does a single period of bad sleep
last?’’
‘‘How long, in days, is the period of good sleep in
between?’’
‘‘Do you feel like your sleep pattern drifts with respect to
the 24 hour day? If yes, can you describe how it drifts?’’
‘‘Do you ever take naps during the day? Or if you are
employed or have other commitments, do you have a
strong desire to nap during the day?’’
‘‘Do you nap more during periods of bad sleep?’’
(iii) the Pittsburgh Sleep Quality Index (PSQI), a validated
index which produces a number from 0–21 with higher
scores indicating increasing sleep problems (a score of
greater than five or more being indicative of poor sleep
[34]);
(iv) the Munich Chronotype Questionnaire (MCTQ) [35];
(v) the Horne-O ¨ stberg Morningness–Eveningness Question-
naire (MEQ) [36];
(vi) the extended Seasonal Pattern Assessment Questionnaire
(SPAQ+) to screen for Seasonal Affective Disorder (SAD.)
[37,38]
Details of the cause of participant’s vision loss, along with their
degree of visual impairment, were obtained from the RNZFB
membership list and were confirmed by participants at the time of
survey. Demographics and lifestyle variables were recorded
(including age (years), sex, BMI, ethnicity (see Table 1 for
categories), domicile deprivation rating (NZDep), self-reported
depression, caffeinated beverages (drinks/day), alcohol consump-
tion (standard units/week), smoking (cigarettes/day) and recrea-
tional drug use (Y/N)). Data were entered directly into a purpose
designed Microsoft Access database and exported into Microsoft
Excel for analysis.
Analysis
Sleep habits and problems. Subject groups (RLP, LP, FS)
were compared with regard to (i) total sleep duration (hours), (ii)
sleep timing (using the midpoint of sleep), (iii) chronotype (MCTQ
score and MEQ scores) and (iv) PSQI. Covariates in the initial
model included: work, ethnicity, NZDep, self-reported depression,
and alcohol consumption. A parsimonious model was found using
backward elimination (based on the R
2 criterion). Generalised
Additive Models (GAMs) were used to examine possible non-
linearities in the explanatory variables, but effects were quantified
using General Linear Model (GLM) (using an identity link
structure and Gaussian errors).
The number of self-reported sleep complaints reported by
individuals within each group were analysed by GLM (log link,
quasi-Poisson error). Age (years), sex and BMI were blocked across
the groups. The model also controlled for a variety of covariates
including ethnicity, deprivation (NZDep), depression, work (days/
week) and alcohol consumption (drinks/week).
Prevalence data. The RLP, LP and FS groups were initially
tested, using x
2 tests for homogeneity, for the prevalence of the
following factors:
(i) specific sleep disorders,
(ii) SAD,
(iii) consulting doctor about sleep problems,
(iv) sleep medication use.
If a significant difference between groups was found, it was
further investigated using t-tests for differences in proportions (with
Bonferroni corrections for multiple comparisons).
Software. The calculations were undertaken with SPSS




Of the total 11,500 members of the RNZFB, we attempted to
contact 456 people in the RLP group and 325 people in the LP
group. Of these, 197 people in the RLP group and 177 in the LP
group were contactable, and mentally and physically able to
participate in the survey. Participation rates were high, with 87%
and 88%, respectively, completing the survey.
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shown in Table 1. The mean age of 55 years reflects the
demographic of the membership of the RNZFB, with a large
number of its members suffering from age-related visual problems
such as macular degeneration. The major ethnic group participat-
ing in the survey was NZ European. The second largest ethnic
group was Ma ¯ori, with 15% and 8% of respondents in the RLP and
LP groups, respectively, identifying their first ethnicity as Ma ¯ori.
Unsurprisingly, employment rates in the fully sighted control
group were higher than either of the blind or visually impaired
groups. This difference in employment status was particularly
pronounced in the 18–65 year old age range, with 52% and 54%
of people in the RLP and LP group working at least one day a
week compared to 92% in the FS controls.
While participants in the RLP and LP groups were well
matched for domicile deprivation (no evidence of difference in
means), the average deprivation rating of FS controls (4.960.24,
SEM) was lower than the RLP (6.260.2, SEM) and LP (6.460.2,
SEM) groups, indicating a higher standard of living.
The ten most common causes of blindness/visual impairment are
shown in Table 2. Traumatic/surgical injury is the most common
cause of blindness in the RLP group, accounting for a quarter of the
cases, while macular degeneration is the most common cause in the
LP group, again accounting for a quarter of the cases.
No overall differences in psychological complaints or disorders
were detected between the three groups. The most frequent
psychological complaint in all three groups was depression, with 4%
of RLP, 8% of LP and 2% of sighted controls reporting depression.
Sleep and the Prevalence of Sleep Disorders
Sleep habits. Sleep duration did not differ between the three
groups. The mean sleep duration was 7.960.2 (SEM) hours in
RLP, 8.260.18 hours in LP and 7.960.01 hours in the FS
controls. A non-linear effect of age on sleep duration (irrespective
of group) was evident in the data, with a minimum sleep duration
at the age of 50 (Figure 1). There was no evidence that self-
reported depression had an effect on sleep duration (p=0.36) or
Table 1. Demographics of the participants in the survey (total n=469).
Reduced Light Perception Light Perception Sighted
No. % No. % No. %
Total 157 156 156
BMI Mean (SE) 26 (0.56) 26 (0.48) 26 (0.40)
NZDep Mean (SE) 6.21 (0.21) 6.40 (0.20) 4.9 (0.24)
Sex Male 87 55 85 54 85 54
Female 70 45 71 46 71 46
Age 0–20 17 11 17 11 17 11
21–40 18 11 17 11 20 13
41–60 57 36 52 33 54 35
61–80 42 27 44 28 43 28
81+ 23 15 26 17 22 14
Mean (SE) 55 (1.84) 56 (1.84) 55 (1.84)
Ethnicity NZ European 120 76 133 85 146 94
Maori 24 15 12 8 6 4
Pacific 4 3 4 3 0 0
Indian 4 3 2 1 2 1
Asian 1 1 3 2 2 1
Other 4 3 2 1 0 0
Work Yes 71 45 64 41 100 64
No 86 55 92 59 56 36
Data are shown as raw numbers and percentages (where appropriate). Where means are given, the standard error is shown in parentheses.
doi:10.1371/journal.pone.0022073.t001
Table 2. Most common causes of blindness/visual
impairment.
RLP LP
Cause No. % Cause No. %
Traumatic/surgical injury 37 24 Macular degeneration 39 25
Glaucoma 15 10 Retinitis pigmentosa 18 12
Congenital 14 9 Congenital 14 9
Retinal detatchment 12 8 Diabetic retinopathy 8 5
Diabetic retinopathy 10 6 Glaucoma 8 5
Macular degeneration 7 4 Stroke/aneurism/blood clot 5 3
Haemorrhage 5 3 Cataracts 5 3
Cataracts 5 3 Traumatic/surgical injury 4 3
Oxygen at birth 4 3 Oxygen at birth 4 3
Retinoblastoma 4 3 Albinism 4 3
Other 44 28 Other 47 30
Total 157 Total 156
Table indicating the ten most common causes of blindness/visual impairment
in the two main groups surveyed (RLP – reduced conscious light perception
and LP – conscious light perception in both eyes).
doi:10.1371/journal.pone.0022073.t002
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significant difference was, however, found in sleep timing between
the RLP and FS groups (p=0.003); but the magnitude of this
difference was small (average mid-sleep: RLP – 2:30 a.m. 65 min;
LP – 2:40 a.m. 65 min; FS - 2:50 a.m. 65 min). Mean
chronotypes were indistinguishable across the groups with
Horne-O ¨ stberg scores of 6460.8, 6460.7 and 6360.8 in RLP,
LP and FS, respectively (p=0.413). Participants self-reporting
depression had a Horne-O ¨ stberg score 5.3 (61.98) points lower
than those not reporting depression but this effect was independent
of study group. Daytime napping was reported in 67% of the RLP
group compared to 59% of LP and 47% of FS participants.
Furthermore, 40% of RLP respondents napped more during
periods of bad sleep compared to 21% of LP and 14% of FS
participants.
Sleep disturbances. The two different measures of sleep
disturbance used in the current survey (self-reported sleep
disturbance and PSQI) both indicated a higher prevalence of
disordered sleep in RLP and LP subjects compared to FS controls.
Subjects in the RLP group self-reported experiencing an
average of 5.0 sleep disturbances per person compared with 4.3
in the LP group and 2.7 in the FS controls. More sleep
disturbances were reported in the RLP (p,0.001) and LP
(p,0.001) subjects compared to FS controls. There was also a
trend towards more sleep disturbances in the RLP subjects than in
the LP group (p=0.074). The distribution of sleep disturbances in
the sighted controls was highly positively skewed. While 91% and
85% of RLP and LP subjects reported having two or more sleep
disorders during their life, only 65% of FS controls did so
(Figure 2).
There was strong evidence that depression was an important
variable when predicting the number of sleep complaints
(p=0.003), with participants with depression reporting on average
32% (95% confidence interval 10% to 58%) more sleep
complaints than those without depression. However, this effect
did not influence the difference in sleep disturbances between the
three study groups.
PSQI scores confirmed the higher rate of sleep disorders in
RLP and LP subjects, with a mean PSQI of 7.660.35 in the RLP
group compared with 6.760.32 in the LP group and 5.360.29 in
the FS controls (Figure 3). Both the RLP (p,0.001) and LP
(p=0.007) subjects were different from the FS controls, with a
trend for PSQI to be higher in the RLP group than in the LP
group (p=0.077). There was no evidence that PSQI was
influenced by self-reported depression (p=0.45). Irrespective of
group, each day a person worked per week correlated with a
0.3 point improvement in their PSQI score, however there is no
evidence that working had an effect on the prevalence of drifting
sleep (p=0.31).
A breakdown of the incidence of self-reported sleep disorders
and PSQI score as a function of total level of vision is given by
Table 3.
The different rates of self-reported sleep disorders in RLP and
LP subjects compared to FS controls (with higher rates in the
RLP and LP groups) were caused, almost exclusively, by
problems with sleep timing, insomnia and increased sleep latency
(Table 4). In contrast, levels of sleep-disordered breathing,
bruxism and sleepwalking/talking were similar across the three
groups (Table 4).
When investigating the prevalence of potential circadian-related
problems in more depth, it was particularly noteworthy that self-
reported drifting sleep (used as an indicator of free-running sleep
patterns) was reported in 26% of RLP subjects, 21% of LP subjects
and only 4% of sighted controls. Totally blind subjects i.e. those
with no light perception in either eye (NLP-NLP), who are the
most likely to have free-running sleep disorders, self-reported
similar levels of drifting sleep to the overall RLP group (most of
whom have light perception in one eye) at 27%.
The number of permanent sleep problems was higher in the FS
controls than the two blind/visually impaired groups (46% vs c.
33%) (Table 5). By contrast, intermittent sleep problems were far
more common in the RLP and LP groups (Table 5). Regular
patterns in intermittent sleep disturbances were most commonly
reported in the RLP group. In this group, the mean period
between the start of one stretch of bad sleep and the next was 21
days (which, assuming a free-running clock, would equate to an
average free-running period of 25.14 hours).
The RLP and LP groups were 2.41 (odds ratio 2.41, 95%
confidence interval 1.5 to 3.9) and 1.63 (odds ratio 1.63, 95%
confidence interval 1.0 to 2.61) times more likely to have
unconventional sleep timing problems, respectively, than the FS
control group. Drifting sleep was 7.3 (odds ratio 7.3, 95%
confidence interval 3.2 to 19.9) and 6.0 (odds ratio 6.0, 95%
confidence interval 2.6 to 16.4) times more likely to occur in the
RLP and LP groups (respectively) than in the FS controls.
Seasonal Affective Disorder. Rates of Seasonal Affective
Disorder (SAD) and sub-syndromal Seasonal Affective Disorder
(SSAD) (as determined by SPAQ+) in the sighted group were
similar to those obtained from previous studies [38,40]. While total
rates of SSAD plus SAD were similar in the three groups (RLP
12.7%, LP 14.7% and S 10.2%), the data revealed a trend towards
an increased rate of the more serious SAD diagnosis in RLP
subjects (5%) compared to the LP (1.9%) and FS (0%) groups. A
latitudinal cline in SAD rates was not apparent within the range
that is found in New Zealand (35.08uS to 46.6uS).
Sleep Disturbances in Ma ¯ori. Five percent of the members
of the RNZFB identify their ethnicity as Ma ¯ori. Rates of Ma ¯ori
participation in the survey were high at 11%. In the RLP and LP
groups, rates of Ma ¯ori participation were 15% and 8%,
Figure 1. Partial residual plot showing the effect of age on total
nightly sleep duration of all subjects (n=469). No differences in
sleep duration were found between the three different subject groups.
Dashed lines indicate 95% confidence intervals.
doi:10.1371/journal.pone.0022073.g001
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higher than non-Ma ¯ori. Fifty-eight percent of all Ma ¯ori RLP
respondents (14 people) and 25% of Ma ¯ori LP respondents (3
people) indicated drifting sleep. The odds ratio for drifting sleep in
RLP and LP Ma ¯ori compared to NLP and LP non-Ma ¯ori is thus
3.7 (95% confidence interval 1.7 to 7.5).
Prevalence of Sleep Medication Use. In order to assess the
severity of sleep problems, participants were asked whether they
had consulted a doctor about them. Once again, rates were much
higher in the RLP and LP groups (39% and 31% of people
reporting sleep problems had consulted their doctor about
treatment) compared to 17% of FS controls (there was strong
evidence of differences between RLP and FS, and LP and FS
groups, p,0.005).
Of the people seeking treatment from their doctor for their sleep
disturbances, the vast majority (90% RLP, 75% LP and 65% FS)
were prescribed medications to help them sleep. The most
commonly prescribed sleep medication was Zopiclone, followed
by low dose benzodiazepines and tricyclics (Table 6). Melatonin
was prescribed infrequently: 4% of RLP, 2% of LP and 0% of FS
subjects were prescribed melatonin. This corresponds to a
maximum of 11% (n=6) (in the RLP group) of the prescribed
sleep medication (Table 6). Of those people who reported drifting
sleep (i.e. potential free-runners), a maximum of 15% (again in the
RLP group) had been prescribed melatonin.
Discussion
The paucity of data on the prevalence of sleep disorders in the
blind, and specifically circadian-related sleep disorders, makes it
difficult to put into context the extent of these problems, and the
importance of research designed to provide effective treatment.
Those blind individuals with circadian-related sleep disorders who
are fortunate enough to receive appropriate chronotherapeutic
treatment from a clinician with a sound knowledge of circadian
biology (or by virtue of participating in a research trial), report vast
improvements not only in objectively and subjectively measured
sleep but also in their quality of life [8,10,16,23,25,26,28].
Here, our aim was to extend current international efforts to
understand the prevalence of sleep disorders in the blind in New
Zealand, a first-world country with a small well-educated
population of four million people. We believe these data give
useful insight into the extent of circadian-related sleep problems in
the blind in New Zealand, and may also provide adequate statistics
for use in larger Western countries (such as Britain and the US)
where the organizational structures through which resources are
delivered to blind and visually impaired people are not as
homogeneous.
Despite a lower sample size than some previous studies (14, 21)
our study is novel in that participants in all three groups were
matched for domicile deprivation rating, something not possible in
Figure 2. Distribution and frequencies of self-reported sleep complaints across the three subject groups. RLP – reduced light
perception, LP – light perception in both eyes, FS – fully sighted. In each case, the mean number of sleep complaints is indicated by a vertical dashed
line.
doi:10.1371/journal.pone.0022073.g002
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chronotype and on sleep medication and melatonin use.
The strong non-linear influence of age on sleep duration
(irrespective of level of vision) is in line with previous findings that
sleep duration shortens with age. No significant differences in sleep
habits were noted between the fully sighted and blind/visually
impaired group and, unlike the survey by Leger [21], no
truncation of total sleep duration in the blind/visually impaired
group was seen. The data did, however, indicate a far higher
incidence of sleep disorders in the blind and visually impaired
population, with the RLP group averaging twice as many sleep
problems as the FS controls (p,0.001), along with poorer sleep.
While the number of sleep complaints in depressed patients was
elevated across all groups, self-reported depression did not account
for the differences between groups and did not influence the
overall rates of sleep complaints. Mean global PSQI scores of FS
subjects were at the upper limit of ‘good sleepers’ at 5.3 (defined as
a score of ,5 [34]), while RLP at 7.6 and LP at 6.7 were sleeping
worse than the sighted controls. The source of these sleep
problems is not caused by differences in rates of depression,
respiratory-related sleep problems, grinding teeth or sleepwalking/
talking, but can be attributed almost entirely to problems of sleep
timing and sleep onset insomnia (see Table 4).
Identifying sleep phase disorders (such as ASPD and DSPD) by
survey (Horne-O ¨ stberg or MCTQ) is commonplace. It is deemed
far more difficult to identify free-running sleep disorder without
objective assessments of sleep timing and a marker of the circadian
clock such as the melatonin rhythm [16], which is obviously not
possible in the context of a survey. Our efforts to conduct a
telephone-based survey were justified in the main by being able to
describe exactly to participants what we meant by drifting sleep
patterns. Specific questions on drifting sleep, the intermittent or
permanent nature of sleep disturbances, and the period of time
between episodes of poor sleep were added with the aim of
ensuring that we could robustly determine the presence or absence
of a free-running sleep disorder. Through this technique, we
believe we have obtained as accurate an assessment of the
prevalence of self reported free-running sleep disorder as is
possible without objective measures of sleep timing and circadian
phase. We consider that the higher incidence of identified ‘free-
run’ in our blind and visually impaired population (25% RLP,
21% LP), compared to the 17% found by Leger [21], and the
lower rates in the sighted population (FS 4% compared to 8% by
Leger), to be a true reflection of the extent of this disorder. We
speculate that the divergent rates are due to strengths in our study
design and our focus on questions aimed to identify free-run
clearly.
The high levels of intermittent sleep disturbances in the RLP
group (Table 5), the fact that these epochs of poor sleep were
accompanied by increased daytime napping, and the period of
recurrence of poor sleep further support the contention that the
sleep-wake cycle is free-running in this group. The mean period (in
days) between stretches of poor sleep for the RLP group, at 21
days (which equates to an average free-running period of
25.14 hours), was within the range of previously documented
free-running periods for the RLP group [12,15,28,41]. In the LP
and FS subjects, the average reported duration was much shorter
(12–14 days), which would equate to either a free-running period
Figure 3. Distribution and frequencies of PSQI scores across the three subject groups. RLP – reduced light perception, LP – light
perception in both eyes, FS – fully sighted. In each case, the mean PSQI score is indicated by a vertical dashed line.
doi:10.1371/journal.pone.0022073.g003
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only way of confirming a free-run in these people would be to
record a marker of their circadian phase over several days or
weeks (see, for example, [15]).
Rates of SAD and SSAD in our sighted population were similar
to those reported from Australia and Europe [38,40]. As might be
expected for a relationship of seasonality with long winter nights,
previous studies have shown that the prevalence of SAD and
SSAD is correlated with latitude. However, the latitudinal cline for
winter depression stops at about 38uN, which could explain why
prevalence studies farther north have failed to find such an effect
Table 3. Incidence of self-reported sleep disturbances and mean Pittsburgh Sleep Quality Index (PSQI) in the six different sub-
groups of the blind and visually impaired respondents.
NPL-NPL NPL -LP NPL-S LP-LP LP-S S-S
No. % No. % No. % No. % No. % No. %
Total
respondents 63 27 67 19 22 115
Sleep Problem
Snoring 40 64 14 52 43 64 4 21 10 46 55 48
Apnoea 9 14 8 30 8 12 2 11 1 4.5 11 9.6
Restless sleep 40 64 18 67 40 60 11 58 14 64 65 57
Unconventional sleep times 33 53 16 59 37 55 3 16 6 27 60 52
Difficulty falling asleep 34 54 18 67 29 43 9 47 14 64 47 41
Awakenings during sleep 54 86 26 96 51 76 15 79 19 86 88 77
Inappropriate early morning wakening 40 64 21 78 33 49 13 68 9 41 51 44
Sleep walk/talk 15 24 5 19 10 15 8 42 4 18 17 15
Non-restorative sleep 31 49 16 59 31 46 8 42 11 50 53 46
Daytime somnolence 33 52 14 52 33 49 4 21 5 23 44 38
Anxiety preventing falling asleep 21 33 16 59 19 28 4 21 10 46 31 27
Bruxism 5 8 6 22 8 12 4 21 1 4.5 25 22
Other 15 24 7 26 19 28 1 5.3 5 23 18 16
PSQI
Respondents 51 24 62 15 20 111
Mean PSQI (SE) 8.31 (0.57) 8 (0.81) 6.95 (0.44) 8.27 (0.80) 7.7 (1.0) 6.25 (0.58)
RLP (reduced conscious light perception) is shown in the first three columns; LP (conscious light perception in both eyes), is shown in the second three columns. Data
are shown as raw numbers and percentages (where appropriate). Where means are given, the standard error is shown in parentheses.
doi:10.1371/journal.pone.0022073.t003
Table 4. Statistically significant differences in the rates of self-
reported sleep disturbances across the three subject groups.
Disorder RLP-LP RLP-S LP-S
Apnoea ns ns ns
Bruxism ns ns ns
Sleep walking/talking ns ns ns
Restless sleep ns ***p,0.001 *** p,0.001
Difficulty falling asleep ns ***p,0.001 *p=0.033
Awakenings during sleep ns ***p,0.001 p=0.099
Anxiety preventing falling
asleep
ns ***p,0.001 * p=0.03
Non-restorative sleep ns ***p,0.001 * p=0.003




Daytime somnolence p=0.066 ***p,0.001 p=0.066
(RLP – reduced light perception, LP – light perception in both eyes, FS – fully
sighted). Asterisks denote significant difference from fully sighted controls
(Chi
2)( *p ,0.05, ** p,0.005 ***p,0.001).
doi:10.1371/journal.pone.0022073.t004
Table 5. Sleep disturbances in respondents with one or more
sleep problem.
RLP LP S
Permanent sleep problems 33%* 32%* 46%
Intermittent sleep problems 67%** 68%** 54%
Desire to sleep at
unconventional times
55%** 43%** 32%
Regular patterns in sleep
disturbances
12%** 7%** 2.6%
Drifting sleep patterns 26%** 21%** 4%
(27% NLP-NLP)
Mean period of sleep
disturbances
21 days 12 days 14 days
Details of the nature and timing of occurrence of sleep disturbances in
respondents reporting they had experienced one or more sleep problems
(n=155 RLP, n=147 LP, n=134 FS). Asterisks denote significant difference from
fully sighted controls (Chi
2)( *p ,0.05, **p,0.005).
doi:10.1371/journal.pone.0022073.t005
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(35.08uS to 46.6uS) only covers some of these lower latitudes,
and so no latitudinal cline should be expected (at least, not in this
small sample).
The trend towards more serious seasonal problems in the RLP
group (evidenced by the higher level of SAD vs SSAD) is
interesting in terms of the association of delayed sleep or delayed
circadian phase in SAD. In general, individuals with delayed phase
are more likely to be depressed or, conversely, depression is often
associated with delayed phase [43]. The blind and visually
impaired have a double biological vulnerability (not to mention
the psychological problems). With reduced light input to the
circadian clock comes the tendency to drift to a phase delayed
position. In winter, light exposure is even less so they drift even
more. Thus, the circadian sleep abnormality coexists with or
perhaps promotes SAD symptoms in susceptible individuals. Our
data suggest that SAD may be an additional problem in people
with impaired light perception. The finding that participants self-
reporting depression had a five point lower Horne-O ¨ stberg score
(more evening chronotype) than those not reporting depression
also fits the associations previously found.
Previous surveys of sleep disorders in New Zealand [31,32] have
demonstrated a higher rate of insomnia symptoms among Ma ¯ori
compared to non-Ma ¯ori. Being Ma ¯ori is an independent risk
factor for reporting sleep complaints including multiple awaken-
ings, early morning awakening and having current sleep problems.
Paine and Gander point out the implications for planning services
that address health inequalities in New Zealand [32]. The data
from our study indicate that attention should be paid to the
probability that blind Ma ¯ori may be a subset of the blind
population who suffer disproportionately from circadian-related
sleep disorders.
The severity of sleep problems in blind and visually impaired
New Zealanders was such that twice the number of people in the
RLP and LP groups had presented to the doctor with a sleep
complaint compared to FS controls, and, consequently, they had
higher rates of sleep medication prescription. In contrast, the rates
of prescribing melatonin were extremely low. Zopiclone was the
most frequently prescribed sleep medication in all three groups,
followed by low dose benzodiazepines and tricyclic antidepres-
sants. Melatonin was used by only 4% of people in the RLP group
and 2% of people in the LP group. None of the participants in our
survey reported receiving any detailed information about timing
their use of melatonin (other than ‘‘take it at bedtime’’) and two
participants were told to stop taking melatonin after a month, even
though they found melatonin greatly helped their sleep timing
problems, as long term use was deemed dangerous (in analogy
with conventional sleep medication).
Safety data on melatonin use are limited. However, reports of
adverse effects of short term melatonin use are rare [44]. A
Cochrane review on the use of melatonin for jet lag does suggest
caution in patients with epilepsy or who are taking warfarin [45].
A recent study of melatonin treatment in children with autism
spectrum disorders also indicated an increase in morning
sleepiness and nocturnal enuresis [46]. Case studies of long term
melatonin use (over years) have not identified any adverse effects
[29].
Melatonin’s actions as a mild sleep promoting drug which works
to shorten sleep latency are known to many. Its primary action as
an entraining drug (or chronobiotic) is virtually unknown outside
the scientific community. As a consequence of this ignorance,
melatonin may be taken at inappropriate times and too-high
doses, with the result that it provides little or no help as an
entraining agent, and may even lead to the aggravation of the
sleep disorder. The extremely low rate of melatonin use in New
Zealand almost certainly reflects a lack of knowledge of
melatonin’s properties by general practitioners, and wariness
about safety, appropriate dosage and timing which stem from not
knowing the basics of circadian physiology. One of the potential
benefits of this study would be programmes to educate New
Zealand practitioners on the appropriate and effective use of
melatonin to alleviate sleep timing problems in the blind
population.
A limitation of our study is that the results obtained are
subjective and participants’ sleep disorders were not clinically
diagnosed. However, the empirical results we have obtained show
that the self-reported incidence of sleep disorders, and sleep timing
disorders in particular, is far higher in the blind population
compared to the sighted population of New Zealand.
While previous studies have indicated a higher incidence of
sleep disorders in people with no perception of light (NLP)
compared to those with light perception, here we have shown that
a reduction in light perception (rather than a total absence) results
in increased sleep disruptions. Self-reported sleep disturbances in
people with reduced light perception are as high as those with no
light perception. Extrapolations from the current study suggest
that in excess of 3,000 blind and visually impaired New Zealanders
may suffer from circadian-related sleep problems and that less
than 15% of them have been prescribed melatonin to combat their
sleep timing problems. This represents a therapeutic gap.
The provision of resources by the RNZFB enables many New
Zealanders with vision disabilities to avoid isolation, hold down
jobs, and participate fully in our community. Efforts to provide
resources to improve their quality of life would be greatly
enhanced by addressing the sleep timing problems that are
evidently common in this group.
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